ClinicalTrials.gg
CompletedNCT05036473Updated Oct 7, 2026Results posted

A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease

A Phase 2 interventional study of WD-1603 Carbidopa-Levodopa Extended-Release Tablets and Placebo in Parkinson Disease, sponsored by Shanghai WD Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Shanghai WD Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
110th of 211
40 · median 47
Started
2021
with 20 others
Phase 2
13 of 279
4 open now
Registered
108th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 110th largest by enrollment of the 211 interventional ones that give a count, is one of 21 that started in 2021, is one of 13 in phase 2, and was the 108th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.

Read the detailed description

Eligible subjects of the study will be randomly assigned into four groups at a ratio of 1:1:1:1: three treatment groups and one placebo group. The subjects will take trial drugs orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • WD-1603
  • Carbidopa-Levodopa Extended-Release Tablets
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female patients with early Parkinson's disease who are over 30 years old and under 75 years old (including cut-off values).
  2. Able to understand and willing to sign an form (ICF) voluntarily.
  3. The diagnosis of Parkinson's disease complies with idiopathic Parkinson's disease (2015 version of MDS Parkinson's disease diagnostic criteria).
  4. Modified Hoehn and Yahr Scale≥1, ≤2.5 points.
  5. Agree to use medically acceptable methods throughout the study and within 1 month after completing the study.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of severe allergic reactions or allergies to levodopa or carbidopa.
  2. Pregnancy or breastfeeding.
  3. Diagnosed as atypical Parkinson's disease or any known secondary Parkinson's syndrome.
  4. The investigator believes that the placebo treatment cannot be tolerated.
  5. Acute psychosis or hallucinations, using any antipsychotic to treat psychosis or clinically obvious depression.
  6. History of epilepsy or epilepsy.
  7. The history of narrow-angle glaucoma.
  8. Subjects with a history of malignant melanoma.
  9. Patients with obvious cognitive impairment.
  10. The investigator believes that there are medical or surgical diseases and patients who are not suitable for participating in clinical trials.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    25/100mg treatment group

    25/100mg WD-1603

    Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets

  • Experimental
    25/150mg treatment group

    25/150mg WD-1603

    Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets

  • Experimental
    2x25/100mg treatment group

    2x25/100mg WD-1603

    Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets

  • Placebo comparator
    placebo group

    placebo are tablets-matching with the same active groups.

    Drug: Placebo

Interventions

  • DrugWD-1603Studies of WD-1603WD-1603 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).

    Also known as: WD-1603

  • DrugPlacebo

    placebo tablets-matching the active groups.

    Also known as: Placebo of WD-1603

06

What researchers measure

Primary outcomes

  1. Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores = greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 27 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.

    Time frame: 27 days- from the baseline to the 27th day

Secondary outcomes

  1. Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores on both parts indicate greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 14 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.

    Time frame: 14 days-from the baseline to the 14th day

  2. Changes in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Motor Experiences of Daily Living) is a 13-item scale used to assess motor experiences of daily living in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part II total score ranges from 0 to 52. Higher scores indicate more severe impairment in motor experiences of daily living (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -52 to +52. A negative change indicates improvement, while a positive change indicates worsening.

    Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day

  3. Changes in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) contains 33 scores based on 18 items and is used to assess motor impairment in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part III total score ranges from 0 to 132. Higher scores indicate more severe motor impairment (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -132 to +132. A negative change indicates improvement in motor impairment, while a positive change indicates worsening.

    Time frame: Baseline to Day 14 and Baseline to Day 27.

  4. Cmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603

    Cmax (Maximum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.

    Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose.

  5. Cmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.

    Cmin (Minimum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.

    Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose

  6. AUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.

    Plasma concentrations of levodopa and carbidopa were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The area under the plasma concentration-time curve from time 0 to τ (AUC0-τ) was calculated using the linear trapezoidal method, where τ is the dosing interval of 5 hours. The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) was calculated as AUC0-t + Clast/λz, where AUC0-t is the AUC from time 0 to the last measurable concentration (Clast), and λz is the terminal elimination rate constant. AUC values are presented in ng\*h/mL for both levodopa and carbidopa. Higher AUC values indicate greater systemic exposure.

    Time frame: 1 day- on the 28th day

  7. Levodopa Plasma Concentration Fluctuation Index of WD-1603.

    Plasma levodopa concentrations were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The fluctuation index was calculated as (Cmax - Cmin) / Cavg, where Cmax is the maximum plasma concentration, Cmin is the minimum plasma concentration, and Cavg is the average plasma concentration calculated as AUC0-τ / τ, with τ = 5 hours. A higher fluctuation index indicates greater fluctuation in plasma levodopa concentration.

    Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose

  8. Adverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603.

    Adverse events (AEs) refer to any untoward medical occurrence in participants, which may present as symptoms and signs, diseases, or abnormal laboratory findings, and may not necessarily have a causal relationship with the study drug. An event was recorded as an AE if at least one of the following criteria was met: (1) accompanying symptoms and signs; (2) examination results requiring treatment measures (such as surgical intervention); or (3) examination results leading to changes in the dosing schedule of the study drug (such as dose change, dosing delay, or discontinuation). The number and percentage of participants with AEs are reported.

    Time frame: 28 days-from baseline to the 28th day.

  9. Beck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease.

    BDI-II scores are collected for safety assessment. BDI-II is a 21-item self-administered survey which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

    Time frame: 28 days-from baseline to the 28th day.

07

Results

Posted Oct 7, 2026

Participant flow

A total of 54 patients with early-stage Parkinson's disease were screened at 5 clinical research centers across China. The first participant was enrolled on November 25, 2021, and the last participant completed the study on December 28, 2022.

Participant flow — Overall Study
Milestone25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Started10101010
Completed9998
Not completed1112
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject1012

Outcome measures

PrimaryChanges in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores = greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 27 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.

Time frame:
27 days- from the baseline to the 27th day
Reported as:
Mean · units on a scale
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.
units on a scale25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.-7.4 ± 2.57-9.2 ± 2.54-14.3 ± 2.54-0.7 ± 2.57
SecondaryChanges in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores on both parts indicate greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 14 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.

Time frame:
14 days-from the baseline to the 14th day
Reported as:
Mean · units on a scale
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.
units on a scale25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.-5.9 ± 2.30-7.9 ± 2.28-11.6 ± 2.280.1 ± 2.31
SecondaryChanges in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Motor Experiences of Daily Living) is a 13-item scale used to assess motor experiences of daily living in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part II total score ranges from 0 to 52. Higher scores indicate more severe impairment in motor experiences of daily living (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -52 to +52. A negative change indicates improvement, while a positive change indicates worsening.

Time frame:
14 days and 27 days-from the baseline to the 14th and 27th day
Reported as:
Mean · units on a scale
Changes in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.
units on a scale25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Change from baseline to Day 14-2.1 ± 0.77-2.6 ± 0.77-2.9 ± 0.77-0.5 ± 0.78
Change from baseline to Day 27-2.2 ± 0.90-3.3 ± 0.91-3.5 ± 0.91-1.2 ± 0.92
SecondaryChanges in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) contains 33 scores based on 18 items and is used to assess motor impairment in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part III total score ranges from 0 to 132. Higher scores indicate more severe motor impairment (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -132 to +132. A negative change indicates improvement in motor impairment, while a positive change indicates worsening.

Time frame:
Baseline to Day 14 and Baseline to Day 27.
Reported as:
Mean · units on a scale
Changes in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.
units on a scale25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Change from baseline to Day 14-3.8 ± 1.84-5.3 ± 1.81-8.6 ± 1.810.5 ± 1.87
Change from baseline to Day 27-5.4 ± 2.05-5.9 ± 2.02-10.8 ± 2.020.8 ± 2.09
SecondaryCmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603

Cmax (Maximum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.

Time frame:
Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose.
Reported as:
Mean · ng/mL
Cmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603
ng/mL25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment Group
Levodopa576.4 ± 204.45751.9 ± 293.761421.1 ± 529.93
Carbidopa70.33 ± 26.77562.83 ± 25.96188.84 ± 102.11
SecondaryCmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.

Cmin (Minimum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.

Time frame:
Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
Reported as:
Mean · ng/mL
Cmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.
ng/mL25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment Group
Levodopa157.62 ± 93.71212.20 ± 95.67413.08 ± 216.41
Carbidopa24.66 ± 13.5424.70 ± 14.5581.94 ± 40.08
SecondaryAUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.

Plasma concentrations of levodopa and carbidopa were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The area under the plasma concentration-time curve from time 0 to τ (AUC0-τ) was calculated using the linear trapezoidal method, where τ is the dosing interval of 5 hours. The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) was calculated as AUC0-t + Clast/λz, where AUC0-t is the AUC from time 0 to the last measurable concentration (Clast), and λz is the terminal elimination rate constant. AUC values are presented in ng\*h/mL for both levodopa and carbidopa. Higher AUC values indicate greater systemic exposure.

Time frame:
1 day- on the 28th day
Reported as:
Mean · ng*h/mL
AUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.
ng*h/mL25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment Group
Levodopa AUC0-τ1681.30 ± 552.672466.67 ± 1051.904711.66 ± 1376.00
Carbidopa AUC0-τ231.00 ± 76.09228.13 ± 96.86718.03 ± 409.25
Levodopa AUC0-∞2935.53 ± 1079.514561.93 ± 1105.607204.29 ± 2420.39
Carbidopa AUC0-∞524.17 ± 470.34457.63 ± 195.541162.49 ± 503.33
SecondaryLevodopa Plasma Concentration Fluctuation Index of WD-1603.

Plasma levodopa concentrations were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The fluctuation index was calculated as (Cmax - Cmin) / Cavg, where Cmax is the maximum plasma concentration, Cmin is the minimum plasma concentration, and Cavg is the average plasma concentration calculated as AUC0-τ / τ, with τ = 5 hours. A higher fluctuation index indicates greater fluctuation in plasma levodopa concentration.

Time frame:
Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
Reported as:
Mean · index
Levodopa Plasma Concentration Fluctuation Index of WD-1603.
index25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment Group
Levodopa Plasma Concentration Fluctuation Index of WD-1603.1.3 ± 0.421.16 ± 0.531.09 ± 0.43
SecondaryAdverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603.

Adverse events (AEs) refer to any untoward medical occurrence in participants, which may present as symptoms and signs, diseases, or abnormal laboratory findings, and may not necessarily have a causal relationship with the study drug. An event was recorded as an AE if at least one of the following criteria was met: (1) accompanying symptoms and signs; (2) examination results requiring treatment measures (such as surgical intervention); or (3) examination results leading to changes in the dosing schedule of the study drug (such as dose change, dosing delay, or discontinuation). The number and percentage of participants with AEs are reported.

Time frame:
28 days-from baseline to the 28th day.
Reported as:
Count of participants · Participants
Adverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603.
Participants25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Adverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603.5273
SecondaryBeck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease.

BDI-II scores are collected for safety assessment. BDI-II is a 21-item self-administered survey which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

Time frame:
28 days-from baseline to the 28th day.
Reported as:
Mean · points
Beck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease.
points25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Beck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease.-1.3 ± 1.87-0.7 ± 1.41-2.1 ± 2.32-1.2 ± 1.48

Adverse events

Collected over From first dose up to 7 days after the last dose (up to a total of 37 days).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25/100mg Treatment Group0/10 (0%)0/10 (0%)5/10 (50%)
25/150mg Treatment Group0/10 (0%)0/10 (0%)2/10 (20%)
2x25/100mg Treatment Group0/10 (0%)0/10 (0%)7/10 (70%)
Placebo Group0/9 (0%)0/9 (0%)3/9 (33.3%)
Most frequent other events
Showing 10 of 20
Most frequent other events
Event25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo Group
Orthostatic hypotensionVascular disorders1/101/103/100/9
DizzinessNervous system disorders1/101/102/100/9
Supraventricular extrasystolesCardiac disorders0/100/100/101/9
Right bundle branch blockCardiac disorders0/100/100/101/9
Clavicle FractureInjury, poisoning and procedural complications0/100/100/101/9
NeuralgiaNervous system disorders1/100/100/100/9
HeadacheNervous system disorders1/100/100/100/9
ConstipationGastrointestinal disorders1/100/100/100/9
NauseaGastrointestinal disorders0/100/101/100/9
VomitingGastrointestinal disorders0/101/100/100/9

Baseline characteristics

All participants who were enrolled and randomized to each study group.

Age, Continuous
Age, Continuous(years)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Mean56.6 ± 9.4760.4 ± 10.6361.7 ± 8.6460.3 ± 12.5459.8 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Female437115
Male673925
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Hispanic or Latino00000
Not Hispanic or Latino1010101040
Unknown or Not Reported00000
Duration of Parkinson's Disease
Duration of Parkinson's Disease(months)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Mean4.5 ± 5.7111.2 ± 18.3113.9 ± 22.829.4 ± 13.379.8 ± 16.07
Modified Hoehn & Yahr Score
Modified Hoehn & Yahr Score(Participants)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
130115
1.501124
2471517
2.5327113
Presence of orthostatic hypotension
Presence of orthostatic hypotension(Participants)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Yes10203
No91081037
Beck Depression Inventory Scale Score
Beck Depression Inventory Scale Score(units on a scale)25/100mg Treatment Group25/150mg Treatment Group2x25/100mg Treatment GroupPlacebo GroupTotal
Mean4.9 ± 3.518.7 ± 11.336.1 ± 3.075.0 ± 4.776.2 ± 6.54
08

Study locations

1 site
  • Shanghai Huashan Hospital
    Shanghai, Shanghai Municipality 200040, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2022, 13 months.

Results were first posted in Oct 2026, 3 years 9 months after primary completion.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2021
First posted
Sep 5, 2021
StartActual
Nov 25, 2021
Primary completionActual
Dec 28, 2022
CompletionActual
Dec 28, 2022
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Start date
Nov 11, 2021→Nov 25, 2021
Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group.Now Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.Time frame: 27 days- from the baseline to the 27th day
Oct 7, 2026
Documents
Secondary outcomes
3 edited, 6 added, 6 removed
What changed in the outcomes
  • EditedTo evaluate levodopa blood concentration fluctuation indexLevodopa Plasma Concentration Fluctuation Index of WD-1603.Time frame: 1 day- on the 28th day → Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
  • EditedTo evaluate reported adverse eventsAdverse Events (AEs) of WD-1603 in patients withPatients With Parkinson's diseaseDisease Treated With WD-1603.Time frame: 28 days-from baseline to the 28th day.
  • EditedTo evaluate Beck Depression Inventory-II (BDI-II) scaleScale of WD-1603 in patients withPatients With Parkinson's diseaseDisease.Time frame: 28 days-from baseline to the 28th day.
  • AddedChanges in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.Time frame: 14 days-from the baseline to the 14th day
  • AddedChanges in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day
  • AddedChanges in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.Time frame: Baseline to Day 14 and Baseline to Day 27.
  • AddedCmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose.
  • AddedCmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
  • AddedAUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.Time frame: 1 day- on the 28th day
  • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th day of the study between each dose group and the placebo group.Time frame: 14 days-from the baseline to the 14th day
  • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th and 27th days of the study between each dose group and the placebo group.Time frame: Day -21- -2, Day -1, Day 14, and Day 27
  • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th and 27th days of the study of MDS-UPDRS-III between each dose group and the placebo group.Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day
  • RemovedTo evaluate CmaxTime frame: 1 day- on the 28th day
  • RemovedTo evaluate CminTime frame: 1 day- on the 28th day
  • RemovedTo evaluate the AUCTime frame: 1 day- on the 28th day
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Start date Nov 11, 2021→Nov 25, 2021
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group.Now Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.Time frame: 27 days- from the baseline to the 27th day
    Secondary outcomes 3 edited, 6 added, 6 removed
    What changed in the outcomes
    • EditedTo evaluate levodopa blood concentration fluctuation indexLevodopa Plasma Concentration Fluctuation Index of WD-1603.Time frame: 1 day- on the 28th day → Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
    • EditedTo evaluate reported adverse eventsAdverse Events (AEs) of WD-1603 in patients withPatients With Parkinson's diseaseDisease Treated With WD-1603.Time frame: 28 days-from baseline to the 28th day.
    • EditedTo evaluate Beck Depression Inventory-II (BDI-II) scaleScale of WD-1603 in patients withPatients With Parkinson's diseaseDisease.Time frame: 28 days-from baseline to the 28th day.
    • AddedChanges in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.Time frame: 14 days-from the baseline to the 14th day
    • AddedChanges in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day
    • AddedChanges in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.Time frame: Baseline to Day 14 and Baseline to Day 27.
    • AddedCmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose.
    • AddedCmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
    • AddedAUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.Time frame: 1 day- on the 28th day
    • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th day of the study between each dose group and the placebo group.Time frame: 14 days-from the baseline to the 14th day
    • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th and 27th days of the study between each dose group and the placebo group.Time frame: Day -21- -2, Day -1, Day 14, and Day 27
    • RemovedTo compare the change from the baseline mean value before the study to the mean value on the 14th and 27th days of the study of MDS-UPDRS-III between each dose group and the placebo group.Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day
    • RemovedTo evaluate CmaxTime frame: 1 day- on the 28th day
    • RemovedTo evaluate CminTime frame: 1 day- on the 28th day
    • RemovedTo evaluate the AUCTime frame: 1 day- on the 28th day
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05036473
Lead sponsor
Shanghai WD Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Nov 25, 2021
Primary completion
Dec 28, 2022
Completion
Dec 28, 2022
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Xiaoxiong(Jim) Wei, MD,PhD
study director · Shanghai WD Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: WD-1603

Start the discussion